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Abstract 
 Mitochondria have been traditionally viewed as the powerhouse of the cell 
due to their major role in the generation of ATP. More recently, mitochondria have 
also been demonstrated to have key roles in a variety of other processes such as 
apoptotic cell death and inflammation. Here we review the different ways in which 
mitochondrial functions impact on cancer. While cancer is comprised of diverse types, 
distinct hallmarks have been defined that are applicable to most cancer types. We 
provide an overview of how mitochondria impact on specific hallmarks; these include 
evasion of cell death, deregulated bioenergetics, genome instability, tumour 
promoting inflammation and metastasis. In addition to discussing the underlying 
mitochondrial roles in each of these processes, we also highlight the considerable 
promise of targeting mitochondrial functions in order to improve cancer treatment.  
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Introduction 
Cancer is a highly diverse disease that is comprised of over two hundred different 
types. Nevertheless, despite this diversity, cancer displays stereotypical traits. These 
hallmarks of cancer, as defined by Hanahan and Weinberg, include, but are not 
limited to, resistance to cell death, tumour-promoting inflammation and deregulated 
metabolism [1]. It is increasingly apparent that mitochondria play key roles in most, if 
not all of the hallmarks of cancer. By virtue of their key biosynthetic functions, 
notably in the generation of ATP, mitochondria are essential for life. More recently, 
mitochondria have been implicated as central regulators of other processes including 
cell death, inflammation, immunity and migration. Perhaps unsurprisingly, these 
functions often interconnect with the metabolic roles of mitochondria. In this review 
we will discuss the roles that mitochondria play in various hallmarks of cancer. For 
reasons of brevity we will focus on mitochondrial regulation of cell death, 
deregulated metabolism, inflammation, genome-instability and migration.  Our 
discussion, will serve to highlight the roles mitochondria play in cancer development 
and progression as well as describing ways in which these can be exploited for 
therapeutic benefit. 
 
Mitochondria and evasion of cell death 
Cell death acts as a potent tumour suppressor mechanism [2]. The best-described 
form of programmed cell death is apoptosis; this process requires caspase protease 
activity leading to rapid cell death this is associated with characteristic morphological 
and biochemical changes. Key tumour suppressor proteins such as p53 engage 
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apoptosis in damaged cells, for example following DNA-damage, to prevent cells from 
becoming transformed. Apoptosis also prevents tumour progression in other ways, 
such as killing cells in nutrient-poor environment or killing cancer cells that detach 
from extracellular matrix and metastasize, a form of death called anoikis. Following 
most apoptotic stimuli, mitochondria are essential for the execution of cell death. 
Through a process called mitochondrial outer membrane permeabilisation or MOMP, 
soluble proteins are released from the mitochondrial intermembrane space that 
actively kill the cell [3] (Figure 1). Chief amongst the killer proteins released from the 
mitochondria is the electron transport protein cytochrome c; following mitochondrial 
release cytochrome c binds the adaptor molecule APAF-1 triggering caspase 
activation and rapid cell death. Importantly, MOMP often leads to cell death 
irrespective of caspase activity, and, as such, represents a point-of-no-return [4].  
 
Because of its deadly consequences, mitochondrial outer membrane integrity is 
highly regulated, mainly through protein-protein interactions between pro- and anti-
apoptotic members of the Bcl-2 protein family [5]. Following an apoptotic stress, pro-
apoptotic BH3-only members of the Bcl-2 protein family relay the stress signal to the 
mitochondria. Here they activate two key activator Bcl-2 proteins, called BAX and 
BAK, that, through a poorly understood mechanism, permeabilise the mitochondrial 
outer membrane, triggering cell death. Anti-apoptotic BCL-2 proteins inhibit 
apoptosis by binding and sequestering BH3-only proteins or by binding and inhibiting 
activated BAX and BAK (Figure 1). 
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Cancer cells evade apoptosis in numerous ways [5]. One common way is by failing 
to respond to an apoptotic stimulus, for example loss of p53 can make cells more 
resistant to DNA-damage induced apoptosis. Alternatively, cancer cells can up-
regulate anti-apoptotic proteins, for example up-regulation of anti-apoptotic Bcl-2 
proteins is commonly observed across diverse tumour types. Importantly, beyond 
promoting cancer, inhibition of mitochondrial apoptosis can also cause resistance to 
anti-cancer treatments, many of which kill cancer cells through the induction of cell 
death [6]. Nevertheless, although inhibition of cell death may promote cancer, many 
cancer cells (particularly haematological malignancies) display increased apoptotic 
sensitivity relative to their healthy, cellular counterparts [7]. Cells in this state, are 
termed "primed-to-die" and are dependent on anti-apoptotic Bcl-2 function for 
survival. Importantly, primed cancer cells are sensitised (relative to normal tissue) to 
apoptosis inducing therapies [8]. This is exploited by new targeted therapies called 
BH3-mimetics that, analogous to BH3-only proteins, neutralise anti-apoptotic BCL-2 
function [9, 10]. In doing so, BH3-mimetics either trigger or sensitise cells to death. 
 
Mitochondria and deregulated cellular energetics 
 Mitochondria are best known for their essential role in powering the cell, 
generating energy in the form of ATP through oxidative phosphorylation (OXPHOS). 
Additionally, mitochondria are key to various other biosynthetic processes, such fatty 
acid synthesis. Over recent years, intense interest has focused on cancer metabolism 
since far from simply having higher rates of metabolism, which might be expected 
due to increased proliferative rates, cancer cells often display alterations in metabolic 
pathways [11]. These alterations can both drive tumourigenesis, by generating so-
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called oncometabolites, or are required to facilitate tumour cell survival in hypoxic or 
nutrient poor environments. Importantly, metabolic re-wiring of tumour cells offers 
cancer-specific drug targets. Here we provide an overview of some of the ways in 
which mitochondrial metabolic pathways are deregulated in cancer.  
 
 In mitochondrial respiration, the carbon fuel acetyl-CoA, generated via 
glycoloysis or fatty acid oxidation, powers the tricaboxylic acid cycle within the 
mitochondrial matrix. The TCA generates NADH and FADH2 that transfer electrons to 
the mitochondrial respiratory chain. This, in turn, leads to the generation of an 
electrochemical gradient over the mitochondrial innermembrane, the energy of 
which generates ATP production by ATP synthase. Besides mitochondrial respiration, 
cells can produce ATP through the process of glycolysis. In terms of ATP generation 
glycolysis is much less efficient than mitochondrial respiration, producing 2 and 36 
molecules of ATP per glucose molecule respectively. Nevertheless, glycolysis serves to 
sustain ATP generation (and cell viability) under conditions where mitochondrial 
respiration is impaired - for example, under low oxygen conditions. The best 
described, and almost universal metabolic adaptation of cancer cells is the 
predominant use of glycolysis to generate ATP even under aerobic conditions - called 
the Warburg effect [11]. Exactly why cancer cells rely on glycolysis in this way remains 
unclear, though a likely reason is the ability of glycoloysis, via intermediary pathways, 
to generate nucleotides, lipids and amino acids, all of which are required for rapid 
proliferation. In addition to the Warburg effect, as we will discuss now, more specific 
alterations in metabolic pathways have been identified in certain cancers, many of 
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which track back to loss or gain of function mutations in key enzymes involved in 
mitochondrial metabolism. 
 
Mutant metabolic enzymes as oncogenic drivers  
 Isocitrate Dehydrogenase (IDH) is an enzyme that catalyses the oxidation of 
isocitrate to α-ketoglutarate, a reaction occurs in the mitochondria (as part of the 
TCA) as well as in the cytoplasm. Recurrent mutations in two isoforms of IDH, IDH1 
and IDH2 have been identified in a variety of tumours, most commonly in acute 
myeloid leukemia (AML) and glioblastoma [12-14]. These mutations in IDH, impart a 
gain of function effect, where α-ketoglutarate is further metabolised to 2-
hydroxyglutarate (2-HG). 2-HG represents an oncometabolite that competitively 
inhibits enzymatic reactions that require α-ketoglutarate as a co-substrate (enzymes 
called 2OG dioxygenases) [13-15]. This has pleiotropic effects all of which possess 
potential oncogenic impact, including effects on epigenetic regulation, histone 
methylation, collagen synthesis and hypoxia induced factor signalling [13-17]. Due to 
their cancer cell specificity, mutant IDH1/2 potentially represent ideal therapeutic 
targets. Accordingly, inhibitors that specifically target mutant IDH1 have recently 
been developed and are currently under clinical evaluation [12]. 
 
 Fumarate hydratase (FH) is a crucial enzyme in the TCA cycle, where it 
converts fumarate to malate. Loss-of-function mutations to FH have been found in 
renal cell cancer, causing an increase in fumarate and decrease in malate and citrate 
[18]. Fumarate is thought to exert oncogenic effects through its ability to activate HIF 
signaling, by directly inhibiting prolyl 4-hydroxylase (PHD) function - the negative 
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regulator of HIF [19]. A key question that arises is how can cells survive the disruption 
of TCA cycle function by loss of fumarate hydratase (FH)?  Addressing this, combined 
approaches of metabolomic analyses with computational modelling, revealed that 
haem oxygenase was required for survival of FH deficient cells, allowing the 
breakdown of accummulated TCA metabolites and partial restoration of NADH 
production [20]. Importantly, inhibiting haem oxygenase activity specifically killed Fh 
deficient tumour cells leading to the prediction that therapeutic exploitation of this 
synthetic lethal relationship should display tumour specific killing. 
 
Cancer promoting mutations in mitochondrial respiratory complex II have also 
been identified. Complex II, is comprised of succinate dehyrdrogenase (SDH) activity 
that links the TCA cycle to the respiratory chain by providing electrons generated 
during the conversion of succinate.  Complex II consists of 4 SDH subunits, mutations 
of which have been reported in paragangliomas, cancers of the neuroendocrine 
system [21]. In a manner analogous to fumarate, accummulated succinate inhibits 
PHD activity leading to HIF activation and pro-oncogenic effects.  
 
Interplay of mitochondrial energetics and tumour suppressor pathways 
Alterations of mitochondrial metabolism via direct mutation of key metabolic 
enzymes appears relatively rare. More commonly, mitochondrial energetics are 
affected by an almost bewildering array of signaling mechanisms. Over recent years, 
both oncogenic and tumour suppressor pathways have been shown to directly effect 
a variety of mitochondrial metabolic pathways, strongly supporting the notion that 
deregulated metabolism underpins cancer development and progression. As an 
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example, here we will focus on the tumour suppressor protein, p53, the activity of 
which is inhibited in the vast majority of cancers [22].  
 
p53 exerts tumour suppressor function through its role as a transcription factor, 
where it up-regulates many genes; these, in turn, lead to an array of tumour 
suppressor functions that include induction of cell-cycle arrest, senescence and 
apoptosis [23]. Amongst other stresses, such as genotoxic insults, nutrient stress can 
activate p53 through numerous means, commonly through activation of AMP-
activated protein kinase (AMPK) leading to direct phosphorylation and 
stabilisation/activation of p53 [24]. Once activated, p53 limits glycolysis through at 
least two means; one is by up-regulating a protein called TIGAR that hydrolyses 
fructose-2,6-biphosphate - an allosteric activator of the key glycolytic enzyme PFK1 
[25]. Secondly, p53 expression can down-regulate several glycolytic enzymes. Beyond 
reducing the amount of glycolysis, p53 also enhances the conversion of pyruvate to 
acetyl-CoA allowing it to enter the TCA cycle and enhance mitochondrial respiration 
[26]. In addition, p53 directly enhances mitochondrial respiration in different ways 
such by up-regulating SCO2, a protein that promotes respiratory complex formation 
and OXPHOS [27, 28].   
 
Clearly, using p53 as an example, there are many ways in which a tumour 
suppressor can impinge on mitochondrial metabolism. In the case of p53, exactly 
what (if any) of these aspects is important for tumour suppression is difficult to 
ascertain, namely due to the additional tumour suppressive functions that p53 also 
possesses.  
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Mitochondria and genomic integrity  
Genome instability and mutations play multiple roles in tumourigenesis ranging 
from promoting cellular transformation through to driving acquired treatment 
resistance. The causes of genome instability are varied and arise from exogenous 
(such as UV light) as well as endogenous insults. Here we will discuss the various ways 
in which, mitochondrial functions can impact on genome integrity as well as 
discussing the potential role of mitochondrial genome stability in cancer. 
 
Mitochondrial Reactive Oxygen Species 
Mitochondria represent a major source of DNA-damaging reactive oxygen species 
(ROS). During oxidative phosphorylation, as a consequence of incomplete reduction 
of oxygen, a variety of ROS are generated that can attack both proteins and nucleic 
acids. The nucleotide guanine is particularly susceptible to ROS-mediated oxidation, 
where it is converted to 8-hydroxyguanine [29]. Although our cells have an array of 
effective DNA-damage response mechanisms, over time accumulated ROS-mediated 
damage can lead to various genomic alterations including mutations, deletions and 
chromosomal translocations (Figure 2A). A number of studies connect mitochondrial 
ROS production to genome instability and its' tumour promoting effects. For example, 
loss of the mitochondrial anti-oxidant protein, SOD2 in vitro potently induces genome 
instability [30]. Moreover, SOD2 heterozygote mice often develop late onset 
mammary tumours, implicating mitochondrial ROS as an oncogenic-driver of these 
tumours [30]. Supporting these findings, inactivating mutations in mitochondrial 
proteins succinate dehydrogenase (complex II) as well as loss of the Sirt4 have also 
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been linked to ROS production and genome instability [31] (Figure 2B). Whilst these 
studies paint a picture that ROS are deleterious, it is important to note that ROS also 
play a variety of key signalling functions in various physiological processes [32].  
 
Mitochondrial DNA Integrity and Cancer 
Although the vast majority of mitochondrial proteins are encoded by the nuclear 
genome, the mitochondrial genome encodes for various proteins that essential for 
respiratory function as well as tRNAs and ribosomal subunits that are required for 
mitochondrial protein synthesis. Relative to nuclear DNA, mitochondria DNA (mtDNA) 
may be more susceptible to DNA-damage for different reasons such as its closer 
physical proximity to ROS generated via OXPHOS as well as the reduced capacity of 
the cell to repair DNA-damage relative to nuclear DNA. In a feed-forward mechanism, 
potentially mutations in mtDNA leading to reduced OXPHOS efficiency and increased 
ROS could have a knock-on effect on both nuclear and mitochondrial genome 
integrity (Figure 2A).  Nevertheless, while numerous somatic and germline 
mitochondrial mutations have been identified in diverse human cancers, it remains 
controversial as to whether these are due to causal or bystanders in tumour 
development. Directly testing this hypothesis is extremely challenging due to the lack 
of means to easily modify the mitochondrial genome. However, some data supports a 
role for maintenance of mitochondrial genome integrity in the regulation of 
oncogenesis. For example, cytoplasts (cells lacking nuclear DNA) that bear an mtDNA 
mutation in the gene encoding ND6 (complex I subunit) have been fused to cells with 
low tumourigencity [33]. This resulted in high ROS induction leading to increased 
tumour outgrowth and apoptotic resistance. Mitochondrial transcription factor A 
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(TFAM) is required for replication and expression of mitochondrial DNA.  While 
complete TFAM loss is incompatible with life, heterozygous deletion is tolerated with 
minimal mtDNA deletion and no overt phenotype [34]. Mitochondria from Tfam 
+/-
 
mice are capable of producing increased ROS (relative to mitochondria from wild-type 
mice)[34]. Most importantly, Tfam heterozygosity promotes tumourigenesis in a 
mouse model of colorectal cancer in a manner that can be inhibited by transgenic 
expression of the anti-oxidant enzyme, mitochondrial-targeted catalase (mCAT) [34]. 
Similarly, decreased mtDNA stability and ROS production have also been linked to the 
genetic ablation of the nuclear encoded mitochondrial RNA helicase (SUV3). Mice that 
are heterozygous for SUV3 exhibit short lifespan and increased tumourigenicity [35].  
 
While these data demonstrate that affecting mitochondrial genetic stability can 
promote cancer (possibly through production of ROS) whether this actually happens 
remains controversial. Typically, hundreds of copies of mtDNA exist per cell leading to 
a mixed pool of mtDNA genotypes in each cell - such a state is termed heteroplasmy. 
Some studies have found selection of specific mtDNA in tumour types, suggesting a 
causal role for mtDNA in tumour suppression. For example, an oncocytoma patient 
with a frameshift mutation in the complex I subunit ND5 displayed enrichment of 
mtDNA with this mutation in tumour compared with healthy tissue, suggesting that it 
conferred selective advantage during tumourigenesis [36]. Supporting this, an 
additional study found that the ND5 frameshift mutation fosters both ROS production 
and tumourigenicity [37]. However, recent large-scale sequencing efforts have failed 
to detect a relationship between specific mtDNA mutations and cancer, finding that 
mutations result from stochastic genetic drift as opposed to being selected for [38]. 
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This study also demonstrated that the majority of mitochondrial mutations likely arise 
during mtDNA replication and are not because of oxidative stress [38]. 
 
Mitochondria, "failed apoptosis" and cancer 
Besides ROS, mitochondria can impact on genome integrity through other means. 
As we have discussed, through the process of MOMP, mitochondria are required for 
apoptosis. The widespread nature of MOMP, such that it often occurs in all 
mitochondria, has led it being viewed as a cellular death sentence [4]. Recent work 
has challenged this idea, finding that MOMP can be engaged in minority of 
mitochondria, so-called minority MOMP [39]. Importantly, cells can survive minority 
MOMP but sustain caspase-dependent DNA-damage that can propagate genomic 
instability, transformation and tumourigenesis (Figure 2B). In line with this, loss of 
caspase-3 has been shown to inhibit tumourigenesis in a chemically induced cancer 
model of skin cancer [40]. These data argue that apoptosis also has a "dark-side" that 
can promote cancer through effects on genome instability.  
 
Mitochondria and inflammation 
The role of inflammation in cancer is complex - although inflammation can clearly 
have tumour inhibitory functions (for example by recruiting immune cells that target 
tumour cells) in many contexts inflammation has oncogenic effects; these include the 
supply of growth factors that promote proliferation as well as matrix-modifying 
effects that promote invasion and metastasis [41]. It is increasingly apparent that 
mitochondria play key roles in many aspects of inflammation, serving as sources on 
molecules that activate inflammatory pathways as well as signalling platforms to 
Page 13 of 29 FEBS Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 14
propagate inflammatory signals. Here we review how mitochondria initiate 
inflammatory pathways through the release of various molecules before discussing 
how this may impact on cancer. 
 
Mitochondria as a source of danger signals   
 Our innate immune systems are geared to recognise diverse sources of danger, 
whether this be an invading bacterium or damaged tissue (which is often secondary 
to infection). Possibly stemming from their bacterial ancestry, mitochondria represent 
a source of several different molecules, termed damage associated molecular 
patterns or DAMPs, that serve to activate inflammation [42]. Mitochondrial DAMPs 
include mtDNA and N-formyl peptides. mtDNA, similar to bacterial DNA, contains 
hypomethylated CpG motifs  that allow it to be recognised by Toll-like receptor, TLR-
9. Consistent with a pro-inflammatory effect, direct injection of mitochondrial (but 
not nuclear) DNA induces neutrophil-dependent lung and liver inflammation [43] 
(Figure 3).  N-formyl peptides bind the receptor FPR-1 to induce cytokine and 
chemokine production [44-46]. These DAMPs act in an extracellular manner but 
equally mitochondrial DAMPs can also act to engage intracellular signalling pathways. 
As discussed extensively, cytochrome c represents a potent mitochondrial DAMP that 
engages apoptosis, via binding to the adaptor molecule APAF-1, following 
mitochondrial release. mtDNA release from mitochondria can also elicit activation of 
various innate immune signaling mechanisms. For example, mtDNA can bind the 
NLRP3 inflammasome leading to caspase-1 dependent processing and secretion of 
the cytokines IL-1β and IL-18 [47] (Figure 3). How mtDNA can escape the 
mitochondria, leading to NLRP3 activation remains controversial. Some studies have 
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argued that it occurs due to apoptotic mitochondrial permeabilisation but this has 
been challenged by others [47, 48]. mtDNA can also serve as an intracellular DAMP to 
activate the interferon pathway in a manner dependent on the signaling molecules 
cGAS and STING (Figure 3). Recent work demonstrates that mtDNA is released from 
mitochondrial under different stresses leading to STING-dependent interferon 
production [49-51].  
 
 Emerging evidence demonstrates a role for inflammatory mediators such as 
STING in the pathogenesis of cancer. For example, STING deficient mice are highly 
resistant to chemically induced skin cancer, in a manner that correlates with reduced 
inflammatory cytokine production [52]. Paradoxically, the loss of STING promotes 
colitis-associated cancer, possibly by enabling microbes to colonise damaged gut 
thereby triggering chronic inflammation [53]. While these, and other studies, 
demonstrate roles for inflammatory mediators in regulating cancer, an outstanding 
question is how important are mitochondria (through the release of DAMPs such as 
mtDNA) in these effects. This is challenging to address given that other DAMPs such 
as extranuclear, genomic DNA can also activate these pathways. Further 
understanding of how DAMPs such as mtDNA are released from stressed 
mitochondria leading to its inhibition, should enable this question to be addressed.  
 
Mitochondrial Roles in Invasion and Metastasis 
Cancer deaths are most often due to secondary tumours that arise by metastatic 
spread of cancer cells from the primary tumour. Metastasis necessitates various 
requirements of a tumour cell that include epithelial to mesenchymal transition, 
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stromal remodelling as well as invasion and migration of cancer cells. Focusing on two 
aspects of mitochondrial biology - bioenergetics and mitochondrial dynamics - we will 
now discuss how mitochondria impact on the metastatic process. 
 
Mitochondrial ROS as a metastatic driver 
The transcription factor HIF-1α can be stabilized by mitochondrial ROS. In 
metastasis this may be important since HIF-1α activity can lead to stromal 
remodelling and connective tissue degradation through matrix metalloproteinase 
(MMP) up-regulation, thereby providing space for cancer cells to migrate and invade 
into surrounding tissue [54, 55] (Figure 4A). Moreover, HIF-1α can up-regulate VEGF 
vascular endothelial growth factor (VEGF) in doing so increasing tumour vasculature 
and facilitating entrance of tumour cells into the bloodstream [54, 56]. In support of a 
pro-metastatic role for mitochondrial ROS, it has previously been shown that mtDNA 
mutations in complex I can increase ROS production leading to angiogenesis and 
metastasis [33]. Furthermore, other work has shown that mitochondrial and oxidative 
phosphorylation, through the production of ROS, are essential for preserving the 
metastatic phenotype by regulating cell plasticity. Porporato and colleagues 
demonstrated that metastatic melanoma produce superoxide due to increased 
OXPHOS leading to electron transport chain overload. Mitochondrial ROS drive the 
activation of the tyrosine kinases Src and Pyk2, essential factors for the migratory 
plasticity of these cells [57] (Figure 4A).  
 
Mitochondrial dynamics and metastasis 
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Mitochondria are highly dynamic organelles that undergo constant rounds of 
fusion and fission. Mitochondrial dynamics play many roles, not least in keeping the 
mitochondrial population healthy by complementing defective mitochondria or by 
enabling their removal through autophagy. Recent evidence also suggests that 
mitochondrial dynamics also play a crucial role in metastasis. Increased expression of 
the mitochondrial fission protein, Drp-1, has been observed in invasive and metastatic 
breast cancer [58]. Supporting a functional importance, inhibition of Drp-1 expression 
(leading to fused mitochondria) was found to inhibit invasion and migration. 
Interestingly, mitochondrial fission is required for formation of lamellopodia (the 
leading edge of migrating cells) [58] (Figure 4B). Because mitochondria accumulate in 
lamellopodia this suggests a localised enrichment of mitochondria is required for 
lamellopodia formation. Supporting these findings, another study has shown that 
mitochondrial distribution is asymmetric in cells migrating towards a chemotactic cue 
[59]. Specifically, mitochondria accumulate towards the leading edge of the migrating 
cell in a manner dependent on mitochondrial fission, since it can be inhibited by 
suppression of Drp-1 (Figure 4B). Importantly, in addition to regulating migration, 
mitochondrial fission has also recently been shown to be required for oncogenic 
transformation, suggesting that targeting fission components such as DRP-1 may have 
multiple anti-tumourigenic effects [60, 61]. 
 
Summary 
In this review we have highlighted some of the ways in which mitochondria impact 
on tumourigenesis. Nevertheless, our discussion represents the tip-of-iceberg, with 
mitochondria playing multifaceted roles in almost every aspect of cancer biology. 
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Most importantly, our basic understanding of how mitochondria impact on cancer is 
already providing novel therapeutic approaches - for example the development of 
drugs that sensitise to mitochondrial apoptosis. Given the selective dependence of 
cancer cells on various mitochondrial roles, mitochondrial-targeting drugs should 
exert both potent and selective anti-cancer activity.  
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Figure Legends 
Figure 1. Mitochondria, cell death and cancer. Following an apoptotic stress, BH3-
only proteins are activated leading to BAX and BAK activation and mitochondrial 
outer membrane permeabilisation (MOMP). MOMP allows release of cytochrome c 
from the mitochondrial intermembrane space. In the cytosol, cytochrome c binds 
APAF-1 leading to its oligomerisation, caspase activation and apoptotic cell death. 
Cancer cells block apoptosis in various ways; loss of p53 can reduce their ability to 
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respond to specific apoptotic stresses or overexpression of anti-apoptotic BCL-2 
proteins can prevent MOMP and cell death. Novel therapeutics, called BH3-mimetics, 
have been developed to neutralise anti-apoptotic BCL-2 function, thereby restoring 
apoptotic sensitivity to cancer cells. 
  
Figure 2. Mitochondria and genomic integrity. A) Hypoxia or mutations in nuclear or 
mtDNA encoded mitochondrial proteins can lead to impairment of the electron 
transport chain and production of reactive oxygen species (ROS). ROS can lead to DNA 
mutations and deletions resulting in genomic instability. B) Sub-lethal stresses 
triggering minority MOMP can result in sub-lethal caspase activation promoting CAD 
activation and DNA damage, thus enhancing genomic instability. 
 
Figure 3. Mitochondria and inflammation. mtDNA can be a robust inducer of 
inflammatory response in either intrinsic or extrinsic manner. Specifically, mtDNA can 
be released by dead cells and activate innate immune cells (neutrophils) acting as a 
DAMP (damage associated molecular pattern). Additionally, cytoplasmic mtDNA can  
activate both the NLRP3 inflammasome and the STING/interferon pathway leading to 
the production of various pro-inflammatory cytokines including IL1 β and IFNα/β. 
 
Figure 4. Mitochondria in migration and metastasis. A) Mitochondrial ROS can 
initiate the activation of the Src/Pyk2 kinases resulting in cytoskeleton remodelling 
and migration. Additionally, ROS can promote angiogenesis and matrix remodelling 
through the activation of HIF-1 targets, such as VEGF and metalloproteinases (MMPs). 
B) Mitochondrial fission in the leading edge of cells can drive migration and 
metastasis in a Drp1-dependent manner.   
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